Status:
COMPLETED
The Expected Advantage of Administering Prophylactic Antibiotics Using Target- Concentration Controlled Infusion
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Seoul Business Agency
Conditions:
Anti-bacterial Agents
Pharmacokinetics
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Preoperative antimicrobial prophylaxis is a key element for the prevention of surgical site infection, the most common type of nosocomial infection in surgical patients. Prophylactic antibiotics are s...
Detailed Description
Parenteral antimicrobial prophylaxis before abdominal surgery for preventing surgical site infection (SSI) is a well-established clinical practice. Prophylactic antibiotics are selected depending on t...
Eligibility Criteria
Inclusion
- over 20 years old
- Patients who are scheduled to undergo colon or rectal surgery
- Patients scheduled to receive cefoxitin as a prophylactic antibiotic
Exclusion
- Known allergies, hypersensitivity, or intolerance to cefoxitin
- Patients with a history of receiving cefoxitin within 3 days of the scheduled surgery time
- Patients receiving therapeutic antibiotics
- eGFR \< 30 ml/min/1.73m2
Key Trial Info
Start Date :
April 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2025
Estimated Enrollment :
2494 Patients enrolled
Trial Details
Trial ID
NCT05253339
Start Date
April 4 2022
End Date
August 28 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, Songpa-Gu,, South Korea, 05505